Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2009-06-16
Target enrollment:
Participant gender:
Summary
This is a safety and tolerability study to investigate the effect of GSK239512 on mild to
moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the
most well tolerated dose in the patients.